Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
City of Hope Medical Center
Novartis
AstraZeneca
Sensei Biotherapeutics, Inc.
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Immunophotonics, Inc.